TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06279494
Drug: MMF
Normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5g bid orally, from -3d to +60d post haplo-HSCT
Study: NCT06279494
Drug: ATG
Normalized name: eATG
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/kg, from -5d to -2d
Study: NCT05707949
Drug: Atogepant
Normalized name: Atogepant
DrugBank: Atogepant (DB16098)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT06452511
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: In the Metformin arm of this study, 50 overweight women with polycystic ovary syndrome (PCOS) and infertility will receive a combination treatment of Letrozole and Metformin. Letrozole, aimed at inducing ovulation, will be administered according to a specified dosage regimen, alongside Metformin, an insulin-sensitizing agent used to manage PCOS, prescribed at a specified dosage regimen. Participants will undergo regular monitoring to assess ovulation and pregnancy outcomes, involving baseline assessments of health status and fertility parameters, ongoing monitoring visits to track ovulation through ultrasound and hormone levels, and final evaluation of ovulation rates and pregnancy outcomes at the study's end. This arm seeks to determine the efficacy of Metformin as an adjunct to Letrozole in improving ovulation induction and pregnancy rates among overweight women with PCOS.
Study: NCT06285370
Drug: Mogamulizumab
Normalized name: mogamulizumab
DrugBank: Mogamulizumab (DB12498)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mogamulizumab will be administered at the dose of 1.0 mg/kg as an intravenous (iv) infusion over at least 1 hour on Days 1, 8, 15, and 22 of Cycle 1 and on Days 1 and 15 of subsequent cycles. Each treatment cycle is set as 28 days. Subjects will continue the treatment of mogamulizumab until any of the criteria for study withdrawal is met.
Study: NCT04528329
Drug: Early-Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: early use of dexamethasone as early as laboratory evidence of high inflammatory markers
Study: NCT04528329
Drug: Late dexamethazone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Use of dexamethasone on deterioration of the cases with increased severity
Study: NCT04968522
Drug: Methylphenidate Hydrochloride
Normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This study is a N-of-1 RCT of currently prescribed stimulant medications for treatment of ADHD symptoms in children with FASD, relative to matched placebo capsules. The Ritalin 10 will be administered at the child's prescribed dose and may include a half tablet (5mg) increment. Ritalin 10 will be encapsulated in full tablet (10mg) or half tablet (5mg) dose.
Study: NCT04968522
Drug: Methylphenidate hydrochloride
Normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This study is a N-of-1 RCT of currently prescribed stimulant medications for treatment of ADHD symptoms in children with FASD, relative to matched placebo capsules. The Ritalin LA will be administered at the child's prescribed total dose. Ritalin LA will be encapsulated.
Study: NCT04968522
Drug: Methylphenidate Hydrochloride 18 MG
Normalized name: methylphenidate hydrochloride 18 MG
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This study is a N-of-1 RCT of currently prescribed stimulant medications for treatment of ADHD symptoms in children with FASD, relative to matched placebo capsules. The Concerta (18mg) will be administered at the child's prescribed total dose. Concerta will be encapsulated.
Study: NCT04968522
Drug: Dexamphetamine sulfate
Normalized name: Dexamphetamine sulfate
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study is a N-of-1 RCT of currently prescribed stimulant medications for treatment of ADHD symptoms in children with FASD, relative to matched placebo capsules. The Dexamphetamine (10mg) will be administered at the child's prescribed total dose. Dexamphetamine will be encapsulated.
Study: NCT05981014
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epirubicin will be administered at 100 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.
Study: NCT05981014
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After administration of cyclophosphamide, fludarabine will then be infused at 25 mg/m\^2 intravenous piggyback (IVPB) daily over approximately 30 minutes for five days, starting five days prior to LNL transfer.
Study: NCT05981014
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel will be administered at 260 mg/m\^2 IV on Day 1 of Cycles 3-6 of the neoadjuvant chemotherapy of the study.
Study: NCT06319560
Drug: Hydroxychloroquine Oral Tablet
Normalized name: hydroxychloroquine Oral Tablet
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200mg daily
Study: NCT06668103
Drug: ABSK043 in combination with Firmonertinib
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Two potential dose levels ：400 mg twice daily （BID） and 800 mg BID) of ABSK043 are prespecified and firmonertinib will be administered orally at a fixed dose of 80 mg once daily (QD).~Patients in dose escalation cohort will receive the ABSK043, 400 mg BID and firmonertinib 80 mg QD as the starting dose for the combination therapy.~Patients in dose confirmation cohort and dose expansion cohort will receive the recommended dose in dose escalation cohort and be evaluated for safety and preliminary anti-tumor activity of the combination therapy.~After Cycle 1, patients will continue to receive combination therapy every 21 days until disease progression, death, loss to follow-up, withdrawal of consent, intolerable toxicity, investigator decision to discontinue treatment, or end of the study.
Study: NCT05413122
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: At enrolment, a 12-week course of varenicline in the commercially available package will be dispensed by a study clinician.
Study: NCT05413122
Drug: Nicotine patch
Normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A 12-week course of nicotine patches and nicotine gum will be dispensed to the participant by the counsellor according to randomization into the c-NRT condition. c-NRT will be provided per label instructions given number of cigarettes the participant smokes per day and will be provided in the commercially available package.
Study: NCT05413122
Drug: Nicotine gum
Normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A 12-week course of nicotine patches and nicotine gum will be dispensed to the participant by the counsellor according to randomization into the c-NRT condition. c-NRT will be provided per label instructions given number of cigarettes the participant smokes per day and will be provided in the commercially available package.
Study: NCT06188676
Drug: Etoposide Phosphate
Normalized name: Etoposide Phosphate
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etopophos
Study: NCT06188676
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Chimeric Anti-CD20 Antibody
Study: NCT06188676
Drug: Vincristine Sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oncovin
Study: NCT06188676
Drug: Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: G-CSF
Study: NCT06188676
Drug: Pegfilgrastim
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: PEG-filgrastim
Study: NCT06188676
Drug: Nivolumab 40 mg in 4 ml Injection
Normalized name: nivolumab 40 MG in 4 ML Injection
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Opdivo
Study: NCT05483465
Drug: Nicotinamide riboside
Normalized name: Nicotinamide riboside
DrugBank: Nicotinamide riboside (DB14933)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral NR, 1g/day per os for 8 weeks
Study: NCT04611776
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab will be administered intravenously during the induction phase and the maintenance phase.
Study: NCT04611776
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin will be administered intravenously during the induction phase.
Study: NCT04611776
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin will be administered intravenously during the induction phase.
Study: NCT04611776
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed will be administered intravenously during the induction phase.
Study: NCT04611776
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine will be administered intravenously during the induction phase.
Study: NCT04611776
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel will be administered intravenously during the induction phase.
Study: NCT04651166
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1g tranexamic acid mixed in 100mL saline or lactated ringer
Study: NCT05296070
Drug: Loncastuximab tesirine 150 µg/Kg
DrugBank: Loncastuximab tesirine (DB16222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be treated with loncastuximab tesirine at a dose of 150 µg/Kg given as an intravenous infusion (given as per treatment guidelines for 30 minutes or longer) on Day 1 (+/- 3 days) of each 21 day cycle for Cycle 1 - 2.
Study: NCT05296070
Drug: Loncastuximab tesirine 75µg/Kg
DrugBank: Loncastuximab tesirine (DB16222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be treated with loncastuximab tesirine at a dose of 75 µg/Kg given as an intravenous infusion (given as per treatment guidelines for 30 minutes or longer) on Day 1 (+/- 3 days) of each 21 day cycle for Cycle 3 - 6.
Study: NCT05645432
Drug: Brexanolone
Normalized name: Brexanolone
DrugBank: Brexanolone (DB11859)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brexanolone IV infusion
Study: NCT06070753
Drug: Cerebrolysin
Normalized name: cerebrolysin
DrugBank: Cerebrolysin (DB16599)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrolysin, 30 ml/day as intravenous infusion, first infusion after completion of EVT. Daily infusion for 10 consecutive days.
Study: NCT06006598
Drug: BI 1584862
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1584862
Study: NCT06006598
Drug: midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: midazolam
Study: NCT04677595
Drug: Capmatinib
Normalized name: CAPMATINIB
DrugBank: Capmatinib (DB11791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg of capmatinib tablets, administered orally twice daily
Study: NCT05633459
Drug: Multiple ascending doses of QRL-201
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple ascending doses of QRL-201 will be intrathecally administered to individuals with sporadic ALS.
Study: NCT05427747
Drug: cefotaxime
Normalized name: Cefotaxime
DrugBank: Cefotaxime (DB00493)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One group will be given cefotaxime and another group meropenem.~The efficacy of antibiotic therapy will be checked with:~* Follow-up paracentesis after 48 hours of initiation of empiric antibiotic treatment showing reduction in neutrophil count of at least 25% .~* Decrease of peritoneal fluid PMN count to \< 250 cells/μ at end of treatment and negative previously positive ascitic fluid culture.
Study: NCT05276960
Drug: Cholecalciferol Pill
Normalized name: cholecalciferol Pill
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose increments according to serum levels determined every 2 months
Study: NCT05683951
Drug: DWKH
Normalized name: Doxylamine, Vitamin B6, Vitamin K1, Hydroxyzine
DrugBank: Doxylamine (DB00366)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of DWKH three times daily
Study: NCT05363956
Drug: Eucalyptus Oil
Normalized name: Eucalyptus oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants were given a dentifrice that had been labeled and tagged with a number. All participants were asked to brush their teeth twice daily with a 1cm line of paste in their respective brushes for two minutes, once in the morning and the other at night, using the modified bass technique.
Study: NCT04565483
Drug: Benralizumab Prefilled Syringe
Normalized name: benralizumab Prefilled Syringe
DrugBank: Benralizumab (DB12023)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients receive BENRALIZUMAB if they meet the criteria for inclusion and non-inclusion at the inclusion visit. Injections take place at the inclusion visit, at 1 month, 2 months, 4 months, 6 months, 8 months, 10 months and 12 months.
Study: NCT06406166
Drug: Lifei Xiaoji Wan
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Lifei Xiaoji Wan consists of ginseng, blackhead, rhubarb, aster, forehu, and thin on
Study: NCT05947435
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid was administered in intravenous or locally within irrigation fluid
Study: NCT05639686
Drug: Tranexamic acid injection
Normalized name: tranexamic acid Injection
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Within 10 minutes of general anesthetic induction, 15mg/kg TXA suspended in 100mL of normal saline will be administered intravenously.
Study: NCT05639686
Drug: Inhalational isoflurane
Normalized name: isoflurane Inhalation Solution
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhalational isoflurane or sevoflurane will be administered as a general anesthetic at the induction of the surgical procedure.
Study: NCT05424822
Drug: JNJ-80948543
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-80948543 will be administered as SC or IV injection.
Study: NCT05926466
Drug: BTZ-043
Normalized name: BTZ-043
DrugBank: BTZ-043 (DB17737)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BTZ-043 belongs to the chemical class of benzothiazinones, and is a promising antibiotic for the treatment of Tuberculosis. Its mechanism of action is based on the covalent inhibition of the enzyme decaprenylphosphoryl-ß-D-ribose-2'-epimerase (DprE1), which is essential for the cell wall assembly of mycobacteria. . Formation of the covalent adduct between BTZ-043 and DprE1 results in inhibition of cell wall biosynthesis and loss of viability of Mycobacteria Tuberculosis. BTZ-043 has been evaluated in three clinical studies: a phase Ia, First Time in Human study (FTIH), a two-stage phase Ib multiple ascending dose (MAD) and phase IIa monotherapy early bactericidal activity (EBA) study, and a human ADME (Absorption/Distribution/Metabolism/Excretion) study.
Study: NCT05926466
Drug: Bedaquiline
Normalized name: Bedaquiline
DrugBank: Bedaquiline (DB08903)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bedaquiline, is a diarylquinoline compound with a novel mechanism of action against MTB, the inhibition of mycobacterial adenosine triphosphate (ATP) synthase. On the 28th of December 2012, the Food and Drug Administration (FDA) granted accelerated approval to SIRTURO® (bedaquiline) tablets as a part of combination therapy in adults with MDR-TB. It is the first to be introduced specifically for the treatment of MDR-TB in combination with other drugs.
Study: NCT05926466
Drug: Delamanid
Normalized name: delamanid
DrugBank: Delamanid (DB11637)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Delamanid is a nitro-dihydro-imidazooxazole derivative that inhibits the synthesis of mycolic acids, a crucial component of the cell wall of MTB. Delamanid has received regulatory approvals in several countries and is currently recommended by WHO for for use in longer MDR- or RR-TB regimens in line with WHO recommendations.
Study: NCT05926466
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxifloxacin belongs to the group of fluoroquinolones (FQ). FQs are a mainstay of MDR-TB treatment, and Moxifloxacin is considered the most potent drug in second line MDR-TB therapy, recently reviewed by WHO, with only moderate pre-existing resistance in the community.
Study: NCT06199544
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Comparing the effect of drugs on symptoms of PCOS
Study: NCT05000736
Drug: palbociclib + aromatase inhibitor
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: palbociclib + aromatase inhibitor therapy
Study: NCT05000736
Drug: fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: fulvestrant monotherapy
Study: NCT00002255
Drug: Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00002255
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002255
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05256069
Drug: Propranolol Pill
Normalized name: propranolol Pill
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive a β-blockade (propranolol pill, 1 mg/kg dosed based on participant weight).
Study: NCT06543082
Drug: Colchicine 0.6 mg
Normalized name: colchicine 0.6 MG
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will take low-dose colchicine (0.6 mg once daily) in addition to ticagrelor maintenance therapy (90 mg twice daily), and discontinue aspirin the day after PCI. They will have an hs-CRP test 1 month after PCI. If the hs-CRP level is below 2 mg/L, colchicine will be discontinued 1 month after PCI. If it is 2 mg/L or higher, colchicine will be continued for 12 months after PCI.
Study: NCT05745233
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intraperitoneal administration of nivolumab Nivolumab 20 mg in normal saline 100ml will be infused intraperitoneally through a temporary catheter in 10 minutes after paracentesis in a weekly interval.
Study: NCT05745233
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intraperitoneal administration of pembrolizumab Pembrolizumab 20 mg in normal saline 100ml will be infused intraperitoneally through a temporary catheter in 10 minutes after paracentesis in a weekly interval.
Study: NCT05642416
Drug: Continuous Infusion of ropivacaine
Normalized name: Uniphyllin Continus
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous infusion of ropivacaine
Study: NCT05642416
Drug: Intermittent bolus of ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent bolus of ropivacaine
Study: NCT00031044
Drug: Enfuvirtide
Normalized name: Enfuvirtide
DrugBank: Enfuvirtide (DB00109)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00031044
Drug: Amdoxovir
Normalized name: Amdoxovir
DrugBank: Amdoxovir (DB06619)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00087464
Drug: Emtricitabine
Normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00087464
Drug: Nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00087464
Drug: Tenofovir disoproxil fumarate
Normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05162430
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.1mg/kg, 0.2mg/kg, 0.3mg/kg, 0.4mg, kg, 0.5mg/kg Propofol was injected to five groups of P1, P2, P3, P4 and P5, respectively, and 5mg dexamethasone sodium phosphate was given to groups P1, P2, P3, P4, P5 and D1 after 30s
Study: NCT05122780
Drug: Antiplatelet Drug
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: acetylsalicylic acid (loading dose 250mg intravenously followed by 75mg orally) + P2Y12 receptor inhibitor (i.e. Clopidogrel, 300 or 600mg loading dose orally, followed by 75 mg orally daily).
Study: NCT05122780
Drug: Nitrates
Normalized name: Nitrates
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.e. nitroglycerine; dosages titrated on blood pressure, ECG, heart rate
Study: NCT05122780
Drug: Anticoagulant
Normalized name: Anticoagulant
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: i.e. warfarin; the selection of the anticoagulant agent will be based on the clinical scenario, contraindications etc
Study: NCT04656184
Drug: ANAKINRA
Normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The patients will receive anakinra, an analogue of the IL-1 receptor antagonist, at a starting dose of 4 mg/kg. If patients are still febrile with 12 hours (H12) of treatment, they will receive a supplementary dose of 2 mg/Kg; otherwise, they will remain at a starting dose of 4 mg/kg. If they are still febrile at H24, they will receive a dose of 8mg/kg; otherwise, they will maintain their dose of 6 mg/kg. Patients with temperature \<38°C at any point between initiation and day 14, but who develop secondary fever due to KD could have further escalation dose of anakinra until a maximum dose of 8mg/Kg. Patients will receive anakinra during 14 days independently of the period of escalation dose if any. After the last escalation dose, if any necessary, the primary criteria will be measured. Patients not responding to anakinra will follow usual standard care and will complete information related to all the study visits